Drug Type Synthetic peptide |
Synonyms Locilex, Pexiganan, Pexiganan acetate (USAN) + [2] |
Target- |
Mechanism Cell membrane permeability enhancers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC122H210N32O22 |
InChIKeyKGZGFSNZWHMDGZ-KAYYGGFYSA-N |
CAS Registry147664-63-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic foot infection | Phase 3 | US | 01 Jun 2014 | |
Diabetic foot ulcer | Phase 3 | US | 01 Aug 1994 | |
Diabetic ulcer | Phase 3 | US | 01 Aug 1994 | |
Diabetic Foot | Phase 3 | - | - | |
Impetigo | Phase 3 | US | - | |
Complicated skin and soft tissue infection | Phase 1 | US | - | - |
Phase 3 | 189 | Standard wound care+Topical pexiganan cream 0.8% (Topical Pexiganan Cream 0.8%) | xvvseunozb(wvoyxmfgqz) = llptifykre bociadsxmq (ddbwbhxlrs, wotudwrewa - hduxxojmyn) View more | - | 14 Jun 2017 | ||
Topical placebo cream (Topical Placebo Control) | xvvseunozb(wvoyxmfgqz) = cqetrzumib bociadsxmq (ddbwbhxlrs, kjxxljjllr - fhydszglkh) View more | ||||||
Phase 3 | 200 | Standard wound care+Topical pexiganan cream 0.8% (Topical Pexiganan Cream 0.8%) | tlknjquxtt(krjcaanqov) = hewkexpybm uryfeyoiok (cypqemxzxd, axhttyvqcd - jtvkoarifk) View more | - | 14 Jun 2017 | ||
Topical placebo cream (Topical Placebo Control) | tlknjquxtt(krjcaanqov) = lobffdvdma uryfeyoiok (cypqemxzxd, jagfmlngfc - ymgyffezly) View more |